TherapeuticsMD Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited - in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,433) | $(9,395) |
| Less: Loss from discontinued operations, net of income taxes | (7) | (3,237) |
| Net loss from continuing operations | (2,426) | (6,158) |
| Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities: | ||
| Depreciation and amortization | 409 | 285 |
| Impairment of long-lived assets (Note 4) | 1,261 | — |
| Write-off of patents and trademarks | — | 59 |
| Share-based compensation | 240 | 1,155 |
| Other | 572 | 525 |
| Changes in operating assets and liabilities: | ||
| Other assets | 1,874 | 1,185 |
| Prepaid and other current assets | 17 | (1,241) |
| Accounts payable | 207 | (1,466) |
| Accrued expenses and other current liabilities | (315) | (11,918) |
| Lease liabilities | (755) | (629) |
| Other non-current liabilities | 69 | 82 |
| Total adjustments | 3,579 | (11,963) |
| Net cash provided by (used in) continuing operating activities | 1,153 | (18,121) |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock, net of costs | — | 1,149 |
| Net cash provided by continuing financing activities | — | 1,149 |
| Discontinued operations: | ||
| Net cash used in operating activities | (433) | (22,179) |
| Net cash used in discontinued operations | (433) | (22,179) |
| Net increase (decrease) in cash | 720 | (39,151) |
| Cash and cash equivalents - continuing operations, beginning of period | 4,327 | 49,317 |
| Total cash and cash equivalents, end of period | $5,047 | $10,166 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.